Different effects of statins on induction of diabetes mellitus: An experimental study

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 6211-6223

  Zhao, Wang ^a   Zhao, Shui Ping ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Glucose; Human pancreas islet cell; Human skeletal muscle cells; Insulin; Statins

Indexed keywords

ATORVASTATIN; GLUCOSE TRANSPORTER 2; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE P38; PITAVASTATIN; PRAVASTATIN; PROTEIN KINASE B; ROSUVASTATIN; GLUCOSE; INSULIN; QUINOLINE DERIVATIVE;

ARTICLE; CELL CYCLE G0 PHASE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DIABETES MELLITUS; EXPERIMENTAL STUDY; G1 PHASE CELL CYCLE CHECKPOINT; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; INSULIN RELEASE; MUSCLE CELL; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; CELL CULTURE; CELL CYCLE; CELL SURVIVAL; CHEMICALLY INDUCED; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; INSULIN RESISTANCE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; STRUCTURE ACTIVITY RELATION;

ATORVASTATIN CALCIUM; CELL CYCLE; CELL SURVIVAL; CELLS, CULTURED; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MUSCLE, SKELETAL; PRAVASTATIN; QUINOLINES; ROSUVASTATIN CALCIUM; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84948143701     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S87979     Document Type: Article

References (37)

1. Naveed AS, Henry G, Kausik R, et al. The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. Atheroscler Suppl. 2014;15:1-15.
2. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
3. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet. 2010;375:735-742.
4. Sattar N, Taskinen MR. Statins are diabetogenic-myth or reality? Atheroscler Suppl. 2012;13:1-10.
5. Navarese EP, Buffon A, Andreotti F, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol. 2013;111:1123-1130.
6. Baker WL, Talati R, White CM, et al. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2010;87:98-107.
7. Supale S, Li N, Brun T, et al. Mitochondrial dysfunction in pancreatic beta cells. Trends Endocrinol Metab. 2012;23:477-487.
8. Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? Curr Opin Cardiol. 2011;26:342-347.
9. Koh KK, Sakuma I, Quon MJ, et al. Differential metabolic effects of distinct statins. Atherosclerosis. 2011;215:1-8.
10. Koeks J, Schrauwen P. Muscle mitochondria and insulin resistance: a human perspective. Trends Endocrinol Metab. 2012;23:444-450.
11. Kusminski CM, Scherer PE. Mitochondrial dysfunction in white adipose tissue. Trends Endocrinol Metab. 2012;23:435-443.
12. Rosenbaum D, Dallongeville J, Sabouret P, et al. Discontinuation of statin therapy due to muscular side effects: a survey in real life. Nutr Metab Cardiovasc Dis. 2012;23:871-875.
13. Draeger A, Monastyrskaya K, Mohaupt M, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol. 2006;210:94-102.
14. Golomb BA, Evans MA, Dimsdale JE, et al. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med. 2012;172:1180-1182.
15. Ciaraldi TP, Abrams L, Nikoulina S, Mudaliar S, Henry RR. Glucose transport in cultured human skeletal muscle cells. Regulation by insulin and glucose in nondiabetic and non-insulin-dependent diabetes mellitus subjects. J Clin Invest. 1995;96:2810-2827.
16. 2+ channels in rat islet beta-cells. Br J Pharmacol. 1999;126:1205-1213.
17. Kanda M, Satoh K, Ichihara K. Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol Pharm Bull. 2003;26:1681-1684.
18. Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycemic control. Diabetologia. 2006;49:1881192.
19. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-2016.
20. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atrovastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
21. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
22. Coleman CI, Reinhart K, Kluger J, With CM. The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2008;24:1359-1362.
23. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol. 2010;55:735-1097.
24. Silva MA, Swanson AC, Gandhi PJ, et al. Statin-related adverse events: a meta-analysis. Clin Ther. 2006;28(1):26-35.
25. Silva MA, Mattews ML, Jarvis C, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther. 2007;29(2):253-260.
26. Kawai Y, Sato-Ishida R, Motoyama A, et al. Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus. Drug Des Devel Ther. 2011;5:283-297.
27. Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol. 2011;57:1535-1545.
28. Sheperd J, Blauw CJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360:1623-1630.
29. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New Engl J Med. 2008;359:2195-2207.
30. Furuya DT, Poletto AC, Favaro RR, Martins JO, Zorn TM, Machado UF. Anti-inflammatory effect of atorvastatin ameliorates insulin resistance in monosodium glutamate-treated obese mice. Metabolism. 2010;59:395-399.
31. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature. 1997;389:610-614.
32. Spranger J, Kroke A, Mohlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003;52:812-817.
33. Singh S, Loke YK. Statins and pancreatitis: a systematic review of observational studies and spontaneous case reports. Drug Saf. 2006;29(12):1123-1132.
34. Preiss D, Tikkanen MJ, Welsh P, et al. Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA. 2012;308(8):804-811.
35. Cui X, Xie Y, Chen M, et al. Statin use and risk of pancreatic cancer: a meta-analysis. Cancer Causes Control. 2012;23(7):1099-1111.
36. Gbelcova H, Lenicek M, Zelenka J, et al. Differences in antitumor effects of various statins on human pancreatic cancer. Int J Cancer. 2008;122(6):1214-1221.
37. Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation.2001;104:3046-3051.